Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Merger Talks Shake Pharma Stocks | Raleigh News
AstraZeneca and Bristol Myers Squibb are rumored to be eyeing a $400 billion merger that could birth the world’s biggest drugmaker — but markets reacted the opposite of expected: AstraZeneca’s stock plunged 7%, while Bristol Myers soared to a 52-week high. Why? Bristol Myers is bracing for a patent cliff on blockbuster drugs like Eliquis and Opdivo, making a merger a potential lifeline to absorb future revenue losses. AstraZeneca shareholders are skeptical — they already have a stellar pipeline and see no need to merge with a company facing looming patent expirations. Plus, regulators would…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.